GeneDx Holdings Corp. (WGS)
| Market Cap | 312.64M |
| Revenue (ttm) | 202.57M |
| Net Income (ttm) | -175.77M |
| Shares Out | 26.05M |
| EPS (ttm) | -7.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 253,432 |
| Open | 10.23 |
| Previous Close | 10.39 |
| Day's Range | 10.18 - 12.57 |
| 52-Week Range | 1.16 - 12.57 |
| Beta | 2.82 |
| Analysts | Buy |
| Price Target | 13.00 (+8.33%) |
| Earnings Date | Apr 29, 2024 |
About WGS
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Cor... [Read more]
Financial Performance
In 2023, WGS's revenue was $202.57 million, a decrease of -13.69% compared to the previous year's $234.69 million. Losses were -$175.77 million, -67.98% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for WGS stock is "Buy." The 12-month stock price forecast is $13.0, which is an increase of 8.33% from the latest price.
News
GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset
The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine The Company will also participate in a ...
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the ...
GeneDx to Participate in 44th Annual Cowen Health Care Conference
STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management ...
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margin...
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024...
GeneDx Announces Preliminary 2023 Financial Results
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test...
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene pane...
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management ...
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia...
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the officia...
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn.
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients Partnership allows commercial ...
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
STAMFORD, Conn., July 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia...
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium
STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data...
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
N ew paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyz ing complex regions of the human pan genome
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with...
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics Keynote session to highlight value of ...
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a le...
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding...
GeneDx Announces Reverse Stock Split
STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of direc...
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financi...